DEA Controlled Compounds

Driven by trends in pain management for cancer therapy and in palliative care, as well as an increased access to treatment for neurological disorders (ADHD, Autism), the controlled substance market is expected to grow considerably over the coming years.

Euticals capabilities and equipment

  • DEA registrations for manufacturing, research and export of Schedule I, II and V controlled substances
  • Long DEA relationship
  • High capacity and flexibility
  • Controlled substance vault and DEA manufacturing areas

 Product classes

  • Phenidates
  • Amphetamine derivatives and precursors 
  • Opioid precursors
  • More under development


Euticals S.p.a.
- V.le Milano, 86 - 26900 Lodi | P.I. & C.F. 07254610152 | Cap. Soc. € 40.828.466,30 iv - R.E.A. 1851470 Isc. Reg. Imp. di Milano | Notice >